NMOSD are a group of inflammatory disorders of the CNS characterised by episodes of humoral-mediated inflammation. In concordance with the humoral pathogenesis, plasma exchange has proven to be a beneficial therapy in patients with severe NMOSD attacks [1]. The mechanism of action of plasma exchange involves the removal of different molecules that contribute to relapses of NMOSD, such as autoantibodies, complement proteins, and immune complexes.
In an observational, retrospective study presented by Dr Enrique Gómez-Figueroa (National Institute of Neurology and Neurosurgery, Mexico), all NMOSD patients who were treated with plasma exchange on top of standard methylprednisolone at the institute between 2010-2019 were included [2]. A total of 89 patients (78.7% female) were identified; mean age at onset was 38 years. Clinical syndrome was optic neuritis in 22.4%, longitudinally extensive myelitis in 28.1%, short transverse myelitis in 12.4%, and brainstem syndrome in 3.4% of patients.
The mean time from symptomatic onset to starting plasma exchange was 21 days. After a mean number of 5 plasma exchanges, a significant decrease was noted in median EDSS (6.5 to 6.0; P<0.001). The benefit of plasma exchange was irrespective of the clinical NMOSD disorder.
- Srisupa-Olan T, et al. Mult Scler Relat Disord. 2018 Feb;20:115-121.
- Gomez-Figueroa E, et al. Therapeutic Plasma Exchange Effect on Neuromyelitis Optica Spectrum Disorder. ECF 28th Annual Meeting. Abstract 58.
Posted on
Previous Article
« No support for IVIG as treatment of acute attacks in NMOSD Next Article
Superior effect of ponesimod versus teriflunomide on clinical disease activity and MRI-based outcomes »
« No support for IVIG as treatment of acute attacks in NMOSD Next Article
Superior effect of ponesimod versus teriflunomide on clinical disease activity and MRI-based outcomes »
Table of Contents: ECF 2020
Featured articles
ECF Round-Up Articles
No association between Ig levels and infection in ofatumumab-treated patients with relapsing MS
Defining phenotypes of MS-related cognitive impairment
First long-term efficacy data of a BTK inhibitor
Novel disease-specific scale confirms huge impact of fatigue
Progressive aerobic exercise improves fatigue
Reliable and convenient method to assess cognitive function in MS patients
Tackling unmet MS-related cognitive challenges
Real-world efficacy of ocrelizumab in MS patients
Similar demographics, clinical characteristics, and treatment patterns in German claims study
Decreased EDSS after plasma exchange in NMOSD
No support for IVIG as treatment of acute attacks in NMOSD
Related Articles
December 16, 2020
First long-term efficacy data of a BTK inhibitor
December 16, 2020
ECF 2020 Highlights Podcast
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com